Q2 Solutions is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. QSolutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q2 Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities. To learn more, visit www.q2labsolutions.com.


  • Dive into the global capabilities of this genomics laboratory, from early discovery and biomarker development to late-phase trials and companion diagnostics.

  • Alex Watt, Global Head for Biotech Integrated Laboratory Solutions, and Alan Wookey, Global Head of Companion Diagnostics, discuss how to manage both scientific and operational risk.

  • There are several advantages to incorporating genomic testing into immuno-oncology clinical trials. Watch this video to see Victor Weigman, Q2 Solutions Translational Genomics, discuss how incorporating genomic testing facilitates research and clinical trial design to realize genomics-based medicine. You’ll also learn how genomic testing expands insight into more treatment options based on a patient’s tumor classification.

  • At Q2 Solutions, we treat each sample as if a life depends on it. We offer global Pathology and Histology services to support scientific requirements of oncology clinical trials. Watch this video about our global anatomic pathology clinical trial central lab services including immunohistochemistry, cytogenetics and molecular assays.

  • We offer a broad range of biorepository services and technologies that are tailored to align with our clients’ protocol and storage needs.  Hundreds of customers trust us to preserve the integrity of their biospecimens for as long as they need to store them.  Watch this video to learn more about our global biorepository and specimen management services.

  • Genomics has come a long way from the days of being primarily a discovery tool. It used to be that essentially all the genomic data that was being produced as part of clinical trials was purely exploratory in nature. This is still being done, but now we're also translating those insights into real uses. In this podcast we discuss the use of broad genomic features such as microsatellite instability and tumor mutational burden as biomarkers in addition to specific point mutations that have been in use for some time.